|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||5.01 - 5.01|
|52 Week Range||2.00 - 5.25|
|Beta (3Y Monthly)||0.85|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 13, 2019 - Aug 13, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Enrollment in Third Cohort of PDA Combination Study is Encouraging Preliminary Efficacy Signals Improve with New Data Regarding Second CohortEntire.
Sun BioPharma, Inc. (SNBP), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of pancreatic diseases, today provides an update on the Company’s current clinical trial. Following successful conclusion of the first SBP-101 dose escalation study in heavily pretreated pancreatic cancer patients that showed SBP-101 could be administered safely as monotherapy, a second Phase 1 safety study entitled, “SBP-101 Administered in Combination with Gemcitabine and Nab-paclitaxel in Newly Diagnosed Patients with Metastatic Pancreatic Ductal Adenocarcinoma” was undertaken to evaluate the addition of SBP-101 to front line gemcitabine and nab-paclitaxel treatment.
Enrollment in Second Cohort of PDA Combination Study CompletedNew Funding Totaling $0.8 Million Secured MINNEAPOLIS, May 14, 2019 -- Sun BioPharma, Inc. (OTCQB:SNBP), a.
Front-Line Combination Study with Gemcitabine and Nab-Paclitaxel enrolling second Cohort of Phase 1a Company reinstates founder and Executive Chairman, Dr. Michael Cullen as.
Sun BioPharma, Inc. opens third site in Melbourne, Australia in Front-Line Combination Study of SBP-101 with Gemcitabine and nab-Paclitaxel for the Treatment of Patients with.
Sun BioPharma, Inc. (SNBP), a clinical stage biopharmaceutical company specializing in disruptive therapeutics for pancreatic diseases, announced today that they will present results of a new study entitled “Effect of SBP-101 in a Mouse Model of Cerulein-induced Acute Pancreatitis” at the American Pancreatic Association meeting in Miami, FL on Nov. 1. The study, performed in collaboration with Cedars-Sinai Medical Center in Los Angeles, CA and funded by the National Institutes of Health, evaluated the ability of SBP-101, a polyamine metabolic inhibitor (PMI), to impact the development of acute pancreatitis using different formulations and dosing regimens.
Sun BioPharma, Inc. (SNBP), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of pancreatic diseases, today announces leadership changes in the organization. Effective October 31, 2018, David B. Kaysen is stepping down as President, CEO and Board member of Sun BioPharma, Inc. and its wholly owned subsidiary, Sun BioPharma Australia Pty Ltd. Also, effective October 31, 2018, Michael T. Cullen, MD, MBA, the company’s Executive Chairman, has accepted the additional responsibilities of President and CEO of Sun BioPharma, Inc. and its wholly owned subsidiary, Sun BioPharma Australia Pty Ltd.